Omeros (OMER) Total Debt (2010 - 2026)
Omeros recorded quarterly Total Debt of $52.8 million in Q1 2026, down 22.82% quarter-over-quarter from $68.4 million in Q4 2025, and down 45.74% year-over-year from $97.3 million in Q1 2025.
Omeros' Total Debt history runs 17 years deep, the most recent figure standing at $52.8 million for Q1 2026.
- In Q1 2026, Total Debt fell 45.74% year-over-year to $52.8 million; the TTM figure through Mar 2026 stood at $52.8 million (down 45.74% YoY), while the FY2025 annual figure was $68.4 million, down 24.51% from the prior year.
- Total Debt came in at $52.8 million for Q1 2026 at Omeros, down from $68.4 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $316.7 million in Q3 2023 to a low of $52.8 million in Q1 2026.
- A 5-year average of $193.5 million and a median of $213.2 million in 2023 frame the typical range for Total Debt.
- Across the five-year window, Total Debt increased 0.61% in 2023 and sank 70.82% in 2024, its largest moves.
- Omeros' Total Debt stood at $315.3 million in 2022, then slumped by 32.39% to $213.2 million in 2023, then sank by 57.48% to $90.6 million in 2024, then decreased by 24.51% to $68.4 million in 2025, then slipped by 22.82% to $52.8 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $52.8 million, $68.4 million, and $72.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 52.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.81 Mn |
| Dec 31, 2025 | 68.43 Mn |
| Sep 30, 2025 | 72.08 Mn |
| Jun 30, 2025 | 87.31 Mn |
| Mar 31, 2025 | 97.33 Mn |
| Dec 31, 2024 | 90.64 Mn |
| Sep 30, 2024 | 92.43 Mn |
| Jun 30, 2024 | 94.51 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Dec 31, 2023 | 213.16 Mn |
| Sep 30, 2023 | 316.74 Mn |
| Jun 30, 2023 | 316.25 Mn |
| Mar 31, 2023 | 315.76 Mn |
| Dec 31, 2022 | 315.29 Mn |
| Sep 30, 2022 | 314.82 Mn |
| Jun 30, 2022 | 314.36 Mn |
| Mar 31, 2022 | 313.90 Mn |
| Dec 31, 2021 | 313.46 Mn |
| Sep 30, 2021 | 313.02 Mn |
| Jun 30, 2021 | 312.59 Mn |
| Mar 31, 2021 | 312.16 Mn |
| Dec 31, 2020 | 236.29 Mn |
| Sep 30, 2020 | 232.81 Mn |
| Jun 30, 2020 | 163.37 Mn |
| Mar 31, 2020 | 160.75 Mn |
| Dec 31, 2019 | 158.21 Mn |
| Sep 30, 2019 | 155.77 Mn |
| Jun 30, 2019 | 153.42 Mn |
| Mar 31, 2019 | 153.74 Mn |
| Dec 31, 2018 | 149.87 Mn |
| Sep 30, 2018 | 132.26 Mn |
| Jun 30, 2018 | 130.36 Mn |
| Mar 31, 2018 | 85.55 Mn |
| Dec 31, 2017 | 83.80 Mn |
| Sep 30, 2017 | 83.15 Mn |
| Jun 30, 2017 | 81.76 Mn |
| Mar 31, 2017 | 80.73 Mn |
| Dec 31, 2016 | 79.71 Mn |
| Sep 30, 2016 | 70.48 Mn |
| Jun 30, 2016 | 70.03 Mn |
| Mar 31, 2016 | 50.04 Mn |
| Dec 31, 2015 | 49.84 Mn |
| Sep 30, 2015 | 28.55 Mn |
| Jun 30, 2015 | 30.77 Mn |
| Mar 31, 2015 | 32.93 Mn |
| Dec 31, 2014 | 32.45 Mn |
| Sep 30, 2014 | 32.54 Mn |
| Jun 30, 2014 | 32.37 Mn |
| Mar 31, 2014 | 32.21 Mn |
| Dec 31, 2013 | 20.50 Mn |
| Sep 30, 2013 | 20.40 Mn |
| Jun 30, 2013 | 20.29 Mn |
| Mar 31, 2013 | 20.20 Mn |
| Dec 31, 2012 | 20.10 Mn |
| Sep 30, 2012 | 8.68 Mn |
| Jun 30, 2012 | 10.35 Mn |
| Mar 31, 2012 | 11.97 Mn |
| Dec 31, 2011 | 19.45 Mn |
| Sep 30, 2011 | 15.09 Mn |
| Jun 30, 2011 | 16.59 Mn |
| Dec 31, 2010 | 9.86 Mn |